Serotonin Release in Premotor and Motor PD
NCT05516732 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 42
Last updated 2025-10-07
Summary
In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms
Conditions
- Parkinson Disease
- Parkinson's
- Parkinson's Disease
- Neurodegenerative Diseases
- Neurodegeneration
- Positron Emission Tomography
Interventions
- OTHER
-
Positron Emission Tomography (PET) scan using CIMBI-36 tracer
This scan creates images of regional serotonin release in by using a tracer compound called CIMBI to highlight the brains capacity to release serotonin.
- OTHER
-
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain
- OTHER
-
Positron Emission Tomography (PET) scan using DASB tracer
To create images of the brain using a tracer called DASB, which is a highly selective for serotonin transporters, this highlights serotonin terminals and neurons in the brain.
- OTHER
-
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
- OTHER
-
Lumbar puncture
A lumbar puncture invovles a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
Sponsors & Collaborators
-
University of Exeter
lead OTHER
Principal Investigators
-
Marios M Politis, Professor · University of Exeter
Eligibility
- Min Age
- 25 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-01
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
NCT00387075 ·Status: UNKNOWN ·Phase: PHASE2
-
Neuroplasticity in Parkinson's Disease
NCT05286736 ·Status: RECRUITING
-
Neuroimaging Studies of Depression in Parkinson's Disease
NCT00518258 ·Status: COMPLETED
-
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
NCT01461109 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging in Parkinson Disease Dementia
NCT01052350 ·Status: ACTIVE_NOT_RECRUITING
-
Predictive Value of Multimodal MRI in Parkinson's Disease
NCT05003206 ·Status: UNKNOWN ·Phase: NA
-
Non-motor Symptoms and Brain Dopamine Transporter Binding
NCT02650843 ·Status: ACTIVE_NOT_RECRUITING
-
Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease
NCT01038310 ·Status: COMPLETED
-
Compensatory Mechanisms in Parkinson Disease (PD)
NCT02038608 ·Status: COMPLETED ·Phase: NA
-
Exercise & Brain Energetics in PD
NCT04426786 ·Status: RECRUITING ·Phase: NA
-
Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease
NCT00736671 ·Status: COMPLETED
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
NCT07020026 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation
NCT00169364 ·Status: UNKNOWN ·Phase: NA
-
Exploratory Study of the Expression of the Serotonergic 5-HT4 Receptor in Parkinson's Disease
NCT05916625 ·Status: COMPLETED ·Phase: NA
-
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
NCT00273351 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients
NCT02599753 ·Status: COMPLETED ·Phase: PHASE2
-
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease
NCT02305147 ·Status: RECRUITING
-
Nigrosomal Iron Imaging in Parkinson's Disease
NCT03022357 ·Status: UNKNOWN
-
Non-invasive Diagnosis of Parkinson's Disease
NCT07201610 ·Status: NOT_YET_RECRUITING
-
Measuring Parkinson's Disease Progression
NCT03205956 ·Status: COMPLETED ·Phase: PHASE1
-
CS1P1 PET Studies of Neuroinflammation in Parkinson Disease
NCT06084533 ·Status: ENROLLING_BY_INVITATION
-
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
NCT02243982 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Cerebral Contributions to Symptom Progression in PD
NCT05169827 ·Status: COMPLETED
-
Neuroimaging of Parkinson's
NCT07024875 ·Status: RECRUITING
-
Long-term Longitudinal Imaging of Presynaptic Terminals in PD
NCT06875765 ·Status: RECRUITING ·Phase: NA